Slide 1: Second Quarter 2024 Operating & Financial Results Conference Call / Webinar
Second Quarter 2024 Operating & Financial Results Conference Call / Webinar With additional focus on preliminary patient data and clinical readouts for Phase 2 LP-300 Harmonic Trial August 8th, 2024 4:30 PM Eastern Time NASDAQ :LTRN
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amend ed, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements
Slide 3: Contents and Speakers
Contents Speakers Panna Sharma David Margrave Reggie Ewesuedo CEO and President CFO VP of Clinical Development 01 Introduction 02 2024 Q2 Highlights 03 Financial Highlights 04 Harmonic LP-300 Phase 2 Clinical Trial Highlights 05 Starlight Therapeutics 06 Other Operational Highlights 07 Q&A
Slide 4: 2nd Quarter 2024 Highlights 1 of 3
2024 2 Quarter nd ✓ Active clinical trials across three AI-guided drug candidates with additional ADC-based preclinical Highlights molecules in evaluation for development ✓ Preliminary patient data and clinical readouts for Phase 2 LP-300 Harmonic Trial released showing an 86% 1of 3 clinical benefit
Slide 5: 2nd Quarter 2024 Highlights 2 of 3
2024 ✓ Phase 1 clinical trials for both synthetic lethal drug 2 Quarter nd candidates, LP-184 and LP-284, continue to advance with no dose-limiting toxicities observed in any of the patient cohorts enrolled and over 40 patients dosed to-date Highlights ✓ Achieved significant advancement towards key
Slide 6: 2nd Quarter 2024 Highlights 3 of 3
2024 Starlight Therapeutics, a wholly owned subsidiary of 2 Quarter nd ✓ Lantern Pharma focused on CNS and brain cancers advanced with initiating site selection and feasibility for a Highlights Phase 1B/Phase 2 trial in recurrent GBM with drug candidate, STAR-001 3of 3 ✓ Launched Webinar Wednesdays,
Slide 7: Lantern's diverse AI-driven pipeline of drug programs including RADR collaborations
Lantern’s diverse & unique AI-driven pipeline of 11 drug programs including RADR®️ collaborations and Starlight Therapeutics Lantern Pharma (NASDAQ: LTRN) Orphan Rare Pediatric Lead Candidate Indication Discovery Preclinical Phase I Phase II Designation Disease Non-Small Cell Lung Cancer LP-300 for
Slide 8: Starlight's pipeline is focused on multiple CNS indications
Starlight’s pipeline is focused on multiple CNS indications in both adult and pediatric patients Starlight Therapeutics ADULT CNS CANCERS Orphan Rare Pediatric Lead Candidate Indication Discovery Preclinical Phase I Phase II Designation Disease Glioblastoma (GBM)* STAR-001 Brain Metastases (TNBC)**
Slide 9: Financial updates Q2 2024
Financial updates Q2 2024 Solid financial position and capital efficiency fuel continued growth and give Lantern cash runway into at least Q3 2025 Summary Results of Operations Balance Sheet Highlights & Summary Three Months Ended June 30, (unaudited) 06/30/2024 12/31/2023 2024 2023 (unaudited) Oper
Slide 10: A Review of Initial Phase 2 Patient Results & Future Directions for NSCLC Treatment
A Review of Initial Phase 2 Patient Results & Future Directions for NSCLC Treatment in Never-Smokers The HarmonicTM Trial -- Supporting Material for Release of Initial Clinical Data from First Cohort (n = 7) Dr. R. Ewesuedo, K. Bhatia, PhD, FRCP, & G. Agnello, PhD, D. Margrave and P. Sharma August 8
Slide 11: Schema of LP-300 Phase 2 Open Label, Randomized Clinical Study Design
Schema of LP-300 Phase 2 Open Label, Randomized Clinical Study Design Arm A LP-300 + (Carboplatin + Pemetrexed) Safety Lead-in with Stratification (gender) N=56 After LP-300 + chemotherapy 4 to 6 Pemetrexed 2:1 Randomization Maintenance N=7 Arm B cycles SOC = Carboplatin + Pemetrexed N=28 Study Spon
Slide 12: Clinical Trial Sites – The Harmonic Phase 2 Trial for LP-300
Clinical Trial Sites – The HarmonicTM Phase 2 Trial for LP-300 United States⋕ – Initial Lead in Cohort (n=7) Japan Expansion Cohorts* • Fairfax, VA • National Cancer Center Hospital • Fountain Valley, CA • Okayama University Hospital • Dallas, TX 15-20% of NSCLC new cases are in 33+% of NSCLC new ca
Slide 13: Safety Lead-in for Phase 2 Clinical Trial, Summary
Safety Lead-in for Phase 2 Clinical Trial, Summary No Dose Limiting Toxicities or Serious Adverse Events were observed & Lantern received approval from the DSMB (Data & Safety Monitoring Board) to proceed to next phase of the trial ● Overall, LP-300 in combination with the chemo doublet has been wel
Slide 14: Initial Cohort / Lead-in Phase – Summary Results & Key Takeaways
Initial Cohort / Lead-in Phase – Summary Results & Key Takeaways Tumor LP-300+ KEY PATIENT CHARACTERISTICS Response Carboplatin + Pemetrexed Partial Response 3/7 (43%) ✓ Patients who are never smokers with lung Stable Disease 3/7 (43%) Progressive Disease (clinical) 1/7 (14%) cancer and histopatholo
Slide 15: Percent change in cancer lesion size over time
HarmonicTM Clinical Trial – Percent change in cancer lesion size over time (as measured using RECIST criteria by clinical investigators) Data from 6 out of 7 patients showing Change in cancer target lesion size from baseline clinical benefit in initial lead-in cohort Progressive Disease Cutoff +4% P
Slide 16: Percent change in cancer lesion size by patient
HarmonicTM Clinical Trial – Percent change in cancer lesion size by patient (as measured using RECIST criteria by clinical investigators) Change in cancer target lesion size from baseline Data from 6 out of 7 patients showing clinical benefit in initial lead-in cohort Progressive Disease Cutoff +4%
Slide 17: Initial patient cohort response over time
HarmonicTM Clinical Trial – Initial patient cohort response over time Initial patient responses in the HarmonicTM trial include an 86% disease control rate in the cohort of lead-in patients and a 43% objective response rate (ORR) including one patient maintaining a 50+% reduction in tumor size over
Slide 18: Patient Demographics And Tumor Response Evaluation
Patient Demographics And Tumor Response Evaluation Non-Target Known mutations / Overall Target lesion Time of SUBJECT lesion New lesions TL1 TL2 TL3 TL4 TL5 biomarkers of interest Response (TL) response Scan response ✓ EGFR 107-002 PD NA (Clinical Progression) 9 wks ✓ MSI high not detected -8% -100%
Slide 19: Initial Cohort for Phase 2 – Prior cancer treatments / history & response
Initial Cohort for Phase 2 – Prior cancer treatments / history & response 107-002 107-003 110-001 103-001 110-002 110-003 110-004 Osimertinib Carboplatin Radiotherapy Osimertinib Osimertinib Selpercatinib Osimertinib Keytruda Alimta Radiotherapy Osimertinib Radiotherapy Radiotherapy Osimertinib Selp
Slide 20: Initial Observations From Phase 2 Safety Lead-In Cohort
Initial Observations From Phase 2 Safety Lead-In Cohort ▪ 7 patients enrolled, dosed and evaluated in lead-in phase of study, which is completed ▪ 6 out of 7 patients have had clinical benefit ▪ 3 are partial responses with an average tumor size reduction of ~51% ▪ 3 are stable disease and have resu
Slide 21: Never Smokers Do Not Respond Well to Immunotherapy
Never Smokers Do Not Respond Well to Immunotherapy PD-1 Inhibitor Response by Smoking Status ▪ Relative to smokers with NSCLC, never smokers are less likely to have high expression of PD-L1, a key biomarker for immunotherapies; they are therefore much less likely to be eligible for or respond to suc
Slide 22: Key Highlights of LP-300
Key Highlights of LP-300 LP-300 is being investigated in a Phase 2 clinical LP-300 + Chemo doublet showed increased survival trial, HarmonicTM in never smokers with NSCLC rates over chemo doublet alone in never smoking patient subgroups with NSCLC …modulates receptor tyrosine kinases, DNA damage rep
Slide 23: Appendix: Comparative & Benchmarking Data For NSCLC Patients Treated With Chemo Doublet
Appendix: Comparative & Benchmarking Data For NSCLC Patients Treated With Chemo Doublet (Pemetrexed and Carboplatin Treatment)
Slide 24: Historical Response Data For Pemetrexed + Carboplatin in NSCLC Patients post TKI treatment
Historical Response Data For Pemetrexed + Carboplatin in NSCLC Patients post TKI treatment STUDY ID Hazard Ratio (HR for median ORR (%) median DOR (months) median PFS (months) (Sponsor) (Carboplatin + Pemetrexed) (Carboplatin + Pemetrexed) (Carboplatin + Pemetrexed) PFS) (Carboplatin + Pemetrexed) M
Slide 25: Born from billions of datapoints & AI, Starlight has blockbuster potential
Born from billions of datapoints & AI, Starlight has blockbuster potential to provide new treatment options for 500,000+ patients There are over 120 types of central nervous system (CNS) and brain 5 Year Survival cancers and a majority have no Rates of CNS And Brain Cancers effective treatment optio
Slide 26: Lantern Pharma 2024 Webinar Series – Webinar Wednesdays
Lantern pharma 2024 webinar series – Webinar Wednesdays – featuring world-class collaborators and researchers Future Webinar Wednesdays AUG 28th Harmonic Phase 2 Clinical Trial for Never Smokers with NSCLC – Preliminary patient data and clinical readouts SEP 25th Power of AI in Drug Development – Pr
Slide 27: Publications highlighting the clinical value of RADR insights
Publications highlighting the clinical value of RADR ® insights & de-risking the development of Lantern’s drug candidates POSTER | IMMUNO-ONCOLOGY SUMMIT 2024 LP-184, a Novel Acylfulvene, Sensitizes Immuno-Refractory Triple Negative Breast Cancers (TNBCs) To Anti-PD1 Therapy by Affecting the Tumor M
Slide 28: 2024 Objectives
2024 Objectives A Breakthrough Year for Lantern ● Complete Phase 1a clinical trial for LP-184; commence Phase 1b and investigator led trial(s) T ● Accelerate enrollment in first-in-human clinical trial for LP-284 in NHL + other cancers O ● Commence enrollment of The Harmonic Trial in targeted sites
Slide 29: NASDAQ: LTRN
IR Contact: IR@lanternpharma.com 1-972-277-1136 NASDAQ: LTRN www.lanternpharma.com CONNECT WITH US @LanternPharma linkedin.com/company/lanternpharma linkedin.com/company/lanternpharma